Clinical trial
A Phase Ⅰa Clinical Trial Designed to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Properties of Multiple Doses of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing
NCT06924385 is registered in ClinicalTrials.gov with Xiamen Amoytop Biotech Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ⅰa Clinical Trial Designed to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Properties of Multiple Doses of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing
- Lead sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- April 6, 2025
- Completion date
- January 20, 2026
- Enrollment
- 18 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
preeclampsia